Eikon Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)

EIKN Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001861123 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$484.24M
54,165,030 shares Covers every share class this company has on file.
Insiders on file
2
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$4.30M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
0.89%
insider-held value divided by market capitalisation

What Eikon Therapeutics, Inc. reports

Revenue
—
No revenue figure in this company’s filings.
Net income
—
No annual profit or loss figure is on file for this company.
Employees
384
Yahoo Finance
Why the revenue box is blank

US GAAP has no one “total revenue” tag that every filer uses. A bank reports interest and dividend income separately from non-interest income; closed-end funds, blank-cheque companies and some property trusts report the same way; and a company that has not sold anything yet — a drug developer still in trials, for instance — files no revenue at all. Adding two differently defined income lines together would produce a number that appears in no filing, so we publish a revenue figure only where the filing tags one annual, US-dollar revenue fact we can point at. A blank here means no such tag, not that we failed to look.

Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Eikon Therapeutics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Eikon Therapeutics, Inc..
Insider Reported role Shares Value Last action
Officers who also sit on the board 1
Roger M. Perlmutter Executive 284,857 $3.09M C Conversion of derivative Feb 6, 2026 position reported
Directors 1
Kenneth C. Frazier Board Member 111,111 $1.21M P Open-market purchase Feb 4, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Eikon Therapeutics, Inc. (EIKN) filed a Form 8-K under Item 5.02 (directors and officers) on Aug 3, 2026

Director or officer change filing

The company filed a current report that includes Item 5.02, the item used to report departures, elections or appointments of directors and certain officers, and related pay arrangements. We record only that this filing exists: we have not extracted who left, who joined or whose role changed. Open the filing to read it.

Form 8-K filed Aug 3, 2026, item 5.02. SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 2 rows we hold, 1 are open-market purchases (P) and 0 open-market sales — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Eikon Therapeutics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Feb 6, 2026 Roger M. Perlmutter C Conversion of derivative 284,857 $0.00 $0 SEC filing ↗
Feb 4, 2026 Kenneth C. Frazier P Open-market purchase 111,111 $18.00 $2.00M SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 18 filers hold a position

Who owns Eikon Therapeutics, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 18 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in Eikon Therapeutics, Inc.

Funds, trusts and companies that disclose an ownership position in Eikon Therapeutics, Inc..
Owner Reported role Shares Filed
Column Group IV GP, LP TenPercentOwner 5,780,143 joint
Column Group IV-A, LP TenPercentOwner 5,780,143 joint
Column Group IV, LP TenPercentOwner 5,780,143 joint
Column Group Opportunity III GP, LP TenPercentOwner 5,780,143 joint
Column Group Opportunity III, LP TenPercentOwner 5,780,143 joint
TCG Opportunity III GP, LLC TenPercentOwner 5,780,143 joint
Lux Co-Invest Opportunities II, L.P. TenPercentOwner 2,294,653 joint
Lux Total Opportunities, L.P. TenPercentOwner 2,294,653 joint
Lux Venture Partners V, LLC TenPercentOwner 2,294,653 joint
Lux Ventures V, L.P. TenPercentOwner 2,294,653 joint
Foresite Capital Fund IV, L.P. TenPercentOwner 1,318,983 joint
Foresite Capital Fund V, L.P. TenPercentOwner 1,318,983 joint
Foresite Capital Management IV, LLC TenPercentOwner 1,318,983 joint
Foresite Capital Management V, LLC TenPercentOwner 1,318,983 joint
Foresite Capital Opportunity Fund V, L.P. TenPercentOwner 1,318,983 joint
Foresite Capital Opportunity Management V, LLC TenPercentOwner 1,318,983 joint
Foresite Capital VI-A Management, LLC TenPercentOwner 1,318,983 joint
Foresite Capital VI-A, LLC TenPercentOwner 1,318,983 joint

See the full ownership map — every entity that files as an owner of a US public company.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Eikon Therapeutics, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Eikon Therapeutics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.